Arteritis de las células gigantes. Recomendaciones en Atención Primaria

  1. M. Frías-Vargas 1
  2. A.C. Aguado-Castaño 2
  3. C. Robledo-Orduña 3
  4. A. García-Lerín 4
  5. M.Á. González-Gay 5
  6. O. García-Vallejo 1
  1. 1 Centro de Salud Comillas, Madrid, España
  2. 2 Centro de Salud Babel, Alicante, España
  3. 3 Centro de Salud San Vicente del Raspeig I, Alicante, España
  4. 4 Centro de Salud Almendrales, Madrid, España
  5. 5 Hospital Universitario Marqués de Valdecilla, Santander, España
Show affiliations +
Journal:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Year of publication: 2021

Issue: 4

Pages: 256-266

Type: Article

DOI: 10.1016/J.SEMERG.2021.04.002 DIALNET GOOGLE SCHOLAR

More publications in: Semergen: revista española de medicina de familia

Abstract

Giant cell arteritis is a systemic vasculitis with significant intra and extracranial involvement that, with early diagnosis and treatment in primary care, can improve its prognosis as it is a medical emergency. Our working group on vascular diseases of the Spanish Society of Primary Care Physicians (SEMERGEN) proposes a series of recommendations based on current scientific evidence for a multidisciplinary approach and follow-up in primary care.

Bibliographic References

  • M. González-Gay, M. Ortego-Jurado, L. Ercole, N. Ortego-Centeno Giant cell arteritis: is the clinical spectrum of the disease changing? BMC Geriatrics., 19 (2019), p. 200, 10.1186/s12877-019-1225-9 View Record in ScopusGoogle Scholar
  • F. Ceccato, S. Paira Compromiso de grandes vasos en arteritis de células gigantes Semin Fund Esp Reumatol., 6 (2005), pp. 53-63 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Koster, E. Matteson, K. Warrington Large-vessel giant cell arteritis: diagnosis, monitoring and management Rheumatology., 57 (2018), pp. ii32-ii42 View Record in ScopusGoogle Scholar
  • C. Crowson, E. Matteson Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015 Semin Arthritis Rheum., 47 (2017), pp. 253-256 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J. Lee, S. Naguwa, G. Cheema, M. Gershwin The geo-epidemiology of temporal (giant cell) arteritis Clin Rev Allergy Immunol., 35 (2008), pp. 88-95 CrossRefView Record in ScopusGoogle Scholar
  • M.A. González-Gay, C. García-Porrúa Epidemiology of the vasculitides Rheum Dis Clin North Am., 27 (2001), pp. 729-749, 10.1016/s0889-857x(05)70232-5 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M.A. González-Gay, J.A. Miranda-Filloy, M.J. López-Díaz, R. Pérez-Alvárez, C. González-Juanatey, A. Sánchez-Andrade, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study Medicine (Baltimore)., 86 (2007), pp. 61-68, 10.1097/md.0b013e31803d1764 CrossRefView Record in ScopusGoogle Scholar
  • C.L. Hill, R.J. Black, J.C. Nossent, C. Ruediger, L. Nguyen, J.V. Ninan, et al. Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis Semin Arthritis Rheum., 46 (2017), pp. 513-519 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • T.J. Schwedt, D.W. Dodick, R.J. Caselli Giant cell arteritis Curr Pain Headache Rep., 10 (2006), pp. 415-420 CrossRefView Record in ScopusGoogle Scholar
  • M.C. Cid-Xutglà, J. Hernández-Rodríguez Vasculitis (19ª Ed.)C. Rozman-Borstnar, F. Cardellach (Eds.), Farraeras Rozman. Medicina Interna, 1, Elsevier, España (2020), pp. 1057-1072 View Record in ScopusGoogle Scholar
  • G.G. Hunder, D.A. Bloch, B.A. Michel, M.B. Stevens, W.P. Arend, L.H. Calabrese, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis: is there over-utilization? Arthritis Rheum., 33 (1990), pp. 1122-1128 View Record in ScopusGoogle Scholar
  • G. Ostberg On arteritis with special reference to polymyalgia arteritica Acta Pathol Microbiol Scand Suppl., 237 (1973), pp. 1-59 View Record in ScopusGoogle Scholar
  • M.A. González-Gay, T.R. Vázquez-Rodríguez, M.J. López-Díaz, J.A. Miranda-Filloy, C. González-Juanatey, J. Martín, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica Arthritis Rheum., 61 (2009), pp. 1454-1461 CrossRefView Record in ScopusGoogle Scholar
  • J. Hernández-Rodríguez, G. Espígol-Frigolé, S. Prieto-González, M.A. Alba, M.C. Cid Xutgla Vasculitis sistémicas Vasculitis de gran vaso: arteritis de células gigantes y arteritis de Takayasu. Arteritis de pequeño vaso: vasculitis crioglobulinémica y vasculitis por IgA La abreviatura correcta es: Medicine (Barc.), 12 (2017), pp. 1690-1703 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • D.S. Younger Giant Cell Arteritis Neurol Clin., 37 (2019), pp. 335-344 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • A. Acosta-Mérida, F. Francisco Hernández Diagnóstico y tratamiento de una arteritis temporal en urgencias Semin Fund Esp Reumatol., 13 (2012), pp. 134-141 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • F. Ciccia, A. Rizzo, A. Ferrante, G. Guggino, S. Croci, A. Cavazza, et al. New insights into the pathogenesis of giant cell arteritis Autoimmun Rev., 16 (2017), pp. 675-683 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • C. Weyand, J. Goronzy Clinical practice Giant-cell arteritis and polymyalgia rheumatica N Engl J Med., 371 (2014), pp. 50-57 CrossRefView Record in ScopusGoogle Scholar
  • C.M. Weyand, J.J. Goronzy Immune mechanisms in medium and large-vessel vasculitis Nat Rev Rheumatol., 9 (2013), pp. 731-740 CrossRefView Record in ScopusGoogle Scholar
  • A. Pfeil, P. Oelzner, P. Hellmann The Treatment of Giant Cell Arteritis in Different Clinical Settings Front Immunol., 9 (2019), p. 3129, 10.3389/fimmu.2018.03129 View Record in ScopusGoogle Scholar
  • M.A. González-Gay, T. Pina, D. Prieto-Peña, M. Calderón-Goercke, O. Gualillo, S. Castañeda Treatment of giant cell arteritis Biochem Pharmacol., 165 (2019), pp. 230-239 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • I. Villa, M. Aguado-Bilbao, V.M. Martínez-Taboada Avances en el diagnóstico de las vasculitis de vasos de gran calibre: identificación de biomarcadores y estudios de imagen Reumatol Clin., 7 (2011), pp. S22-S27 View Record in ScopusGoogle Scholar
  • D. González-Tobías, M.V. Zamora-Sánchez Polimialgia reumática Arteritis de Horton AMF., 15 (2019), pp. 640-647 View Record in ScopusGoogle Scholar
  • M.A. González-Gay, S. Barros, M.J. López-Díaz, C. García-Porrúa, A. Sánchez-Andrade, J. Llorca Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients Medicine (Baltimore)., 84 (2005), pp. 269-276 CrossRefView Record in ScopusGoogle Scholar
  • A.T. Borchers, M.E. Gershwin Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment Autoinmun Rev., 11 (2012), pp. A544-A554 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M.A. González-Gay, T.R. Vázquez-Rodríguez, I. Gómez-Acebo, R. Pego-Reigosa, M.J. López-Díaz, M.C. Vázquez-Triñanes, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis Medicine (Baltimore)., 88 (2009), pp. 227-235, 10.1097/MD.0b013e3181af4518 View Record in ScopusGoogle Scholar
  • J.C. Amor-Dorado, J. Llorca, C. García-Porrua, C. Costa, N. Pérez-Fernández, M.A. Gónzalez-Gay Audiovestibular manifestations in giant cell arteritis: a prospective study Medicine (Baltimore)., 82 (2003), pp. 13-26, 10.1097/00005792-200301000-00002 View Record in ScopusGoogle Scholar
  • M.A. González-Gay, C. García-Porrua, A. Piñeiro, R. Pego-Reigosa, J. Llorca, G.G. Hunder Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study Medicine (Baltimore)., 83 (2004), pp. 335-341, 10.1097/01.md.0000145366.40805.f8 View Record in ScopusGoogle Scholar
  • M.A. González-Gay, D. Prieto-Peña, M. Calderón-Goercke, B. Atienza-Mateo, S. Castañeda Giant cell arteritis: more than a cranial disease Clin Exp Rheumatol., 38 (2020), pp. 15-17 View Record in ScopusGoogle Scholar
  • M.A. González-Gay, G. Rubiera, A. Piñeiro, C. García-Porrúa, R. Pego-Reigosa, C. González-Juanatey, et al. Ischemic heart disease in patients from Northwest Spain with biopsy proven giant cell arteritis. A population based study J Rheumatol., 32 (2005), pp. 502-506 View Record in ScopusGoogle Scholar
  • M.A. González-Gay, D. Prieto-Peña, I. Martínez-Rodríguez, M. Calderón-Goercke, I. Banzo, R. Blanco, et al. Early Large Vessel Systemic Vasculitis in Adults Best Pract Res Clin Rheumatol., 33 (2019), p. 101424, 10.1016/j.berh.2019.06.006 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • C. Salvarani, C. Della Bella, L. Cimino, P. Macchioni, D. Formisano, G. Bajocchi, et al. Risk factors for severe craneal ischaemic events in an italian population-based cohort of patients with giant cell arteritis Rhaumatology (Oxford)., 48 (2009), pp. 250-253 View Record in ScopusGoogle Scholar
  • M.A. González-Gay, E.L. Matteson, S. Castañeda Polymyalgia rheumatica Lancet., 390 (2017), pp. 1700-1712, 10.1016/S0140-6736(17)31825-1 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.A. Prior, H. Ranjbar, J. Belcher, S.L. Mackie, T. Helliwell, J. Liddl, et al. Diagnostic delay for giant cell arteritis-a systematic review and meta-analysis BMC Med., 15 (2017), p. 120 View Record in ScopusGoogle Scholar
  • M. Samson, P. Ornetti, B. Bonnotte Arteritis de células gigantes (enfermedad de Horton) - Seudopoliartritis rizomélica EMC - Tratado de medicina, 23 (2019), pp. 1-10 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. González-Gay, C. García-Porrúa, J. Llorca, A. Hajeer, F. Brañas, A. Dababneh, et al. Visual Manifestations of Giant Cell Arteritis: Trends and Clinical Spectrum in 161 Patients Medicine (Baltimore)., 79 (2000), pp. 283-292 View Record in ScopusGoogle Scholar
  • M.A. González-Gay, R. Blanco, V. Rodríguez-Valverde, V.M. Martínez-Taboada, M. Delgado-Rodríguez, M. Figueroa, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment Arthritis Rheum., 41 (1998), pp. 1497-1504 View Record in ScopusGoogle Scholar
  • M.A. González-Gay, S. Castañeda, J. Llorca Giant cell arteritis: Visual loss is our major concern J Rheumatol., 43 (2016), pp. 1458-1461 CrossRefView Record in ScopusGoogle Scholar
  • M.A. González-Gay, M.J. López-Díaz, S. Barros, C. García-Porrúa, A. Sánchez-Andrade, J. Paz-Carreira, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients Medicine (Baltimore)., 84 (2005), pp. 277-290, 10.1097/01.md.0000180043.19285.54 CrossRefView Record in ScopusGoogle Scholar
  • M.J. López-Díaz, J. Llorca, C. Gónzalez-Juanatey, J.L. Peña-Sagredo, J. Martín, M.A. Gonzalez-Gay The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis Semin Arthritis Rheum., 38 (2008), pp. 116-123, 10.1016/j.semarthrit.2007.10.014 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • C. Duftner, C. Dejaco, A. Sepriano, Falzon Louise, W.A. Schmidt, S. Ramiro Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literatura review and meta-analysis informing the EULAR recommendations RMD Open., 4 (2018), p. e000612, 10.1136/rmdopen-2017-000612 CrossRefView Record in ScopusGoogle Scholar
  • C. Dejaco, S. Ramiro, C. Duftner, F.L. Besoon, T.A. Bley, D. Blockmans, et al. EULAR recomemndations for the use of imaging in large vessel vasculitis in clinical practice Ann Rheum Dis., 77 (2018), pp. 636-643 CrossRefView Record in ScopusGoogle Scholar
  • K.T. Calamia, E.L. Matterson, Mazlumzadeh, C.J. Michel, L.E. Mertz, G.G. Hunder Trends in the use of temporal artery biopsy for the diagnosis of giant cell arteritis: experience in 2539 patients at 3 centers over 11 years (abstract) Arthirtis Rheum., 52 (2005), p. S221 Google Scholar
  • C. Mukhtyar, L. Guillevin, M.C. Cid, B. Dasgupta, K. De Groot, W. Gross, et al. European Vasculitis Study Group EULAR recommendations for the management oflarge vessel vasculitis Ann Rheum Dis., 68 (2009), pp. 318-323 CrossRefView Record in ScopusGoogle Scholar
  • Matteson EL, Buttgereit F, Dejaco C, Dasgupta B. Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis.Rheum Dis Clin North Am. 2016;42:75-90. Google Scholar
  • D. Prieto-Peña, I. Martínez-Rodríguez, J. Loricera, I. Banzo, M. Calderón-Goercke, V. Calvo-Río, et al. Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica Semin Arthritis Rheum., 48 (2019), pp. 720-727, 10.1016/j.semarthrit.2018.05.007 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M.A. González-Gay, T. Pina Giant cell arteritis and polymyalgia rheumatica: an update Curr Rheumatol Rep., 17 (2015), pp. 64-67 Google Scholar
  • F. Buttgereit, C. Dejaco, E.L. Matteson, B. Dasgupta Polymyalgia rheumatica and giant cell arteritis: a systematic review J Am Med Assoc., 315 (2016), pp. 2442-2458 CrossRefView Record in ScopusGoogle Scholar
  • L. Martínez-Lado, C. Calviño-Díaz, A. Piñeiro, T. Dierssen, T.R. Vázquez-Rodríguez, J.A. Miranda-Filloyet, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain Medicine (Baltimore)., 90 (2011), pp. 186-193, 10.1097/MD.0b013e31821c4fad View Record in ScopusGoogle Scholar
  • G. Nesher, Y. Berkun, M. Mates, M. Baras, R. Nesher, A. Rubinow, et al. Risk factors for cranial ischemic complications in giant cell arteritis Medicine (Baltimore)., 83 (2004), pp. 114-122, 10.1002/cyto.a.22090 View Record in ScopusGoogle Scholar
  • C.M. Weyand, J.J. Gorozny Giant cell arteritis and polymyalgia rheumatica Ann Intern Med., 139 (2003), pp. 505-515 CrossRefGoogle Scholar
  • C. Salvarani, L. Cimino, P. Macchioni, D. Consonni, F. Cantini, G Bajocchi, et al. Risk factors for visual loss in an Italian population based cohort of patients with giant cell arteritis Arthritis Rheum., 53 (2005), pp. 293-297, 10.1002/art.21075 CrossRefView Record in ScopusGoogle Scholar
  • K.J. Warrington Giant cell arteritis BMJ Best Practice [sede Web] BMJ Publishing Group Limited, London (2018) Disponible en: http://bestpractice.bmj.com/topics/en-gb/177 Google Scholar
  • M.A. González-Gay, T. Pina, D. Prieto-Peña, M. Calderon-Goercke, R. Blanco, S. Castañeda Current and emerging diagnosis tools and therapeutics for giant cell arteritis Expert Rev Clin Immunol., 14 (2018), pp. 593-605 CrossRefView Record in ScopusGoogle Scholar
  • C. Mukhtyar, L. Guillevin, M.C. Cid, B. Dasgupta, K. De Groot, W. Gross, et al. EULAR recommendations for the management of large vessel vasculitis Ann Rheum Dis., 68 (2009), pp. 318-323 CrossRefView Record in ScopusGoogle Scholar
  • A.D. Mahr, J.A. Jover, R.F. Spiera, C. Hernández-García, B. Fernández-Gutiérrez, M.P. Lavalleyet, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis Arthritis Rheum., 56 (2007), pp. 2789-2797, 10.1002/art.22754 CrossRefView Record in ScopusGoogle Scholar
  • C. Ponte, J. Martins-Martinho, R.A. Luqmani Diagnosis of giant cell arteritis Rheumatology (Oxford)., 59 (2020), pp. iii5-iii16 CrossRefView Record in ScopusGoogle Scholar
  • J. Hernández-Rodríguez, M. Segarra, C. Vilardell, M. Sánchez, A. García-Martínez, M.J. Esteban, et al. Elevated production of interleukin-6 is associated with a lower incidence of diseaserelated ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism Circulation., 107 (2003), pp. 2428-2434 View Record in ScopusGoogle Scholar
  • A. García-Martínez, J. Hernández-Rodríguez, G. Espigol-Frigole, S. Prieto-González, M. Butjosa, M. Segarra, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term follow up of patients with giant cell arteritis Arthritis Care Res (Hoboken)., 62 (2010), pp. 835-841 CrossRefView Record in ScopusGoogle Scholar
  • P.M. Villiger, S. Adler, S. Kuchen, F. Wermelinger, D. Dan, V. Fiege, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial Lancet., 387 (2016), p. 1921 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J.H. Stone, K. Tuckwell, S. Dimonaco, M. Klearman, M. Aringer, D. Blockmans, et al. Trial of tocilizumab in giant-cell arteritis N Engl J Med., 377 (2017), p. 317 CrossRefView Record in ScopusGoogle Scholar
  • J. Loricera, R. Blanco, J.L. Hernández, S. Castañeda, A. Mera, E. Pérez-Pampín, et al. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients Semin Arthritis Rheum., 44 (2015), pp. 717-723, 10.1016/j.semarthrit.2014.12.005 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Calderón-Goercke, J. Loricera, V. Aldasoro, S. Castañeda, I. Villa, A. Humbría, et al. Tocilizumab in giant cell arteritis Observational, open-label multicenter study of 134 patients in clinical practice Semin Arthritis Rheum., 49 (2019), pp. 126-135, 10.1016/j.semarthrit.2019.01.003 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Yates, Y.K. Loke, R.A. Watts, A.J. MacGregor Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis Clin Rheumatol., 33 (2014), pp. 227-236, 10.1007/s10067-013-2384-2 CrossRefView Record in ScopusGoogle Scholar
  • F. Kreiner, H. Galbo Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial Arthritis Res Ther., 12 (2010), p. R176, 10.1186/ar3140 CrossRefView Record in ScopusGoogle Scholar
  • C.A. Langford, D. Cuthbertson, S.R. Ytterberg, N. Khalidi, P.A. Monach, S. Carette, et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis Arthritis Rheumatol., 69 (2017), pp. 837-845 CrossRefView Record in ScopusGoogle Scholar
  • M. De Silva, B.L. Hazleman Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study Ann Rheum Dis., 45 (1986), pp. 136-138 CrossRefView Record in ScopusGoogle Scholar
  • R. Conway, L. O’Neill, E. O’ Flynn, P. Gallagher, G.M. McCarthy, C.C. Murphy, et al. Ustekinumab for the treatment of refractory giant cell arteritis Ann Rheum Dis., 75 (2016), p. 1578 CrossRefView Record in ScopusGoogle Scholar
  • L. Quartuccio, M. Maset, G. De Maglio, E. Pontarini, M. Fabris, E. Mansutti, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis Rheumatology (Oxford)., 51 (2012), pp. 1677-1686 CrossRefView Record in ScopusGoogle Scholar
  • V.M. Martínez-Taboada, M. López-Hoyos, J. Narváez, P. Muñoz-Cacho Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis Autoimmun Rev., 13 (2014), pp. 788-794, 10.1016/j.autrev.2014.02.006 ArticeDownload PDFView Record in ScopusGoogle Scholar
  • A. Proven, S.E. Gabriel, C. Orces, W.M. O’Fallon, G.G. Hunder Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes Arthritis Rheum., 49 (2003), p. 703, 10.1002/art.11388 View Record in ScopusGoogle Scholar
  • I. Shbeeb, D. Challah, S. Raheel, Crowson CS1, E.L. Matteson Comparable rates of Glucocorticoid Associated Adverse Events in Patients with Polymyalgia Rheumatica and Comorbidities in the General Population Arthritis Care Res (Hoboken)., 70 (2018), pp. 643-647 View Record in ScopusGoogle Scholar
  • S. Hernández-Baldizón ¿Cómo hacer buen uso del metotrexato en artritis reumatoide? Reumatol Clin., 8 (2012), pp. 42-45 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J. Gómez-Reino, E. Lozano, J.L. Andreu, A. Balsa, E. Batlle, J.D. Cañete, et al. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas Reumatol Clin., 7 (2011), pp. 284-298 ArticleDownload PDFGoogle Scholar
Data source: Dialnet